Matching articles for "Zimhi"
Issue 1746 · January 19, 2026
Nalmefene Autoinjector (Zurnai) for Reversal of Opioid Overdose

Zurnai (Purdue), an autoinjector formulation of the opioid antagonist nalmefene, has been approved by the FDA for intramuscular (IM) or subcutaneous (SC) emergency treatment of known or suspected opioid…

Med Lett Drugs Ther. 2026 Jan 19; 68(1746):10-2 doi:10.58347/tml.2026.1746b
Zurnai (Purdue), an autoinjector formulation of the opioid antagonist nalmefene, has been approved by the FDA for intramuscular (IM) or subcutaneous (SC) emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Naloxone, another opioid antagonist, has been available in single-use syringes for years. Both nalmefene and naloxone are also available in nasal sprays; some naloxone nasal sprays ( Narcan , and others) are available over the counter.
Issue 1687 · October 16, 2023
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose

The FDA has approved an intranasal formulation of the opioid antagonist nalmefene ( Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene,…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):166-7 doi:10.58347/tml.2023.1687b
The FDA has approved an intranasal formulation of the opioid antagonist nalmefene ( Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene, which is available by prescription, is the second opioid antagonist to become available as a nasal spray for this indication; the first was naloxone, which is now available for sale over the counter ( Narcan , and generic). Other nasal spray formulations of naloxone and injectable formulations of nalmefene and naloxone are available by prescription (see Table 2).
Issue 1684 · September 4, 2023 Free
Drugs for Opioid Use Disorder

Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections…

Med Lett Drugs Ther. 2023 Sep 4; 65(1684):137-44 doi:10.58347/tml.2023.1684a
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Issue 1658 · September 5, 2022
Nalmefene Returns for Reversal of Opioid Overdose

The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex , the reference product, was withdrawn from the…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):141-2
The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex , the reference product, was withdrawn from the market in 2008 for commercial reasons.
Issue 1648 · April 18, 2022 Free
Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose

The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone ( Zimhi – Adamis) for emergency treatment of opioid overdose. A single IM or SC injection of the new formulation…

Med Lett Drugs Ther. 2022 Apr 18; 64(1648):61-2
The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone ( Zimhi – Adamis) for emergency treatment of opioid overdose. A single IM or SC injection of the new formulation delivers 5 mg of naloxone; injectable formulations that deliver 0.4 mg or 2 mg of the drug have been available for years. Naloxone is also available in intranasal formulations for the same indication (see Table 1).